{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T14:10:17Z","timestamp":1768745417621,"version":"3.49.0"},"reference-count":37,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2010,8,5]],"date-time":"2010-08-05T00:00:00Z","timestamp":1280966400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epilepsia"],"published-print":{"date-parts":[[2010,10]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold><jats:styled-content>Purpose:<\/jats:styled-content>\u2002<\/jats:bold> \u03b1\u2010Fluoro\u20102,2,3,3\u2010tetramethylcyclopropanecarboxamide (\u03b1\u2010F\u2010TMCD) and \u03b1\u2010Cl\u2010TMCD, are \u03b1\u2010halo derivatives of TMCD, the corresponding amide of a cyclopropane analog of valproic acid (VPA). This study aimed to comparatively evaluate the pharmacodynamics and pharmacokinetics of \u03b1\u2010F\u2010TMCD and \u03b1\u2010Cl\u2010TMCD in rodent models of epilepsy and for antiepileptic drug (AED)\u2013induced teratogenicity. The potential of \u03b1\u2010F\u2010TMCD as an antiallodynic and antinociceptive compound was also evaluated.<\/jats:p><jats:p><jats:bold><jats:styled-content>Methods:<\/jats:styled-content>\u2002<\/jats:bold> \u03b1\u2010F\u2010TMCD and \u03b1\u2010Cl\u2010TMCD were synthesized. \u03b1\u2010Cl\u2010TMCD anticonvulsant activity was evaluated in comparison to VPA in the mouse maximal\u2010electroshock\u2010seizure (MES), Metrazol (scMet), and 6\u2010Hz psychomotor\u2010seizure tests. Neurotoxicity was assessed by the Rotorod\u2010ataxia test. Induction of neural tube defects (NTDs) by \u03b1\u2010Cl\u2010TMCD and \u03b1\u2010F\u2010TMCD was evaluated after intraperitoneal administration to a mouse strain highly susceptible to VPA\u2010induced teratogenicity. The ability of \u03b1\u2010F\u2010TMCD to reduce pain was evaluated in the rat spinal nerve ligation (SNL) model for neuropathic pain and in the formalin test. \u03b1\u2010F\u2010TMCD and \u03b1\u2010Cl\u2010TMCD pharmacokinetics was evaluated following intraperitoneal (40\u2003mg\/kg) and oral (60\u2003mg\/kg) administration to rats.<\/jats:p><jats:p><jats:bold><jats:styled-content>Results:<\/jats:styled-content>\u2002<\/jats:bold> \u03b1\u2010F\u2010TMCD and \u03b1\u2010Cl\u2010TMCD had similar potencies in the 6\u2010Hz test and were more potent than VPA in this model and in the scMet test. Neither induced NTDs, and both exhibited wide safety margins. \u03b1\u2010F\u2010TMCD was active in the two pain models, and was found to be equipotent to gabapentin in the SNL model (ED<jats:sub>50<\/jats:sub>\u2003=\u200337 and 32\u2003mg\/kg, respectively). Comparative pharmacokinetic analysis showed that \u03b1\u2010Cl\u2010TMCD is less susceptible to liver first\u2010pass effect than \u03b1\u2010F\u2010TMCD because of lower total (metabolic) clearance and liver extraction ratio.<\/jats:p><jats:p><jats:bold><jats:styled-content>Conclusions:<\/jats:styled-content>\u2002<\/jats:bold> Based on their potent anticonvulsant activity and lack of teratogenicity, \u03b1\u2010F\u2010TMCD and \u03b1\u2010Cl\u2010TMCD have the potential for development as new antiepileptics and central nervous system (CNS) drugs.<\/jats:p>","DOI":"10.1111\/j.1528-1167.2010.02684.x","type":"journal-article","created":{"date-parts":[[2010,8,6]],"date-time":"2010-08-06T15:49:48Z","timestamp":1281109788000},"page":"1944-1953","source":"Crossref","is-referenced-by-count":6,"title":["Comparative pharmacodynamic and pharmacokinetic analysis of two anticonvulsant halo derivatives of 2,2,3,3\u2010tetramethylcyclopropanecarboxamide, an amide of a cyclic analog of valproic acid"],"prefix":"10.1111","volume":"51","author":[{"given":"Neta","family":"Pessah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Kaufmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boris","family":"Yagen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naama","family":"Hen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bogdan","family":"Wlodarczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard H.","family":"Finnell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meir","family":"Bialer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,8,5]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.21511"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(01)00302-3"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200767180-00007"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1016055517724"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nurt.2006.11.007"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2997"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/03602530600959433"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3959(77)90130-0"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/tera.1420380403"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-60447-8_3"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200767150-00002"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1528-1157.2002.25801.x"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2003.12.001"},{"key":"e_1_2_7_15_1","first-page":"385","article-title":"Metabolism of fenpropathrin in rats","volume":"12","author":"Kaneko H","year":"1987","journal-title":"Nippon Noyaku Gakkaishi"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(98)00084-9"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm901229s"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3959(92)90041-9"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2006.00846.x"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1535-7511.2008.00273.x"},{"key":"e_1_2_7_21_1","first-page":"211","article-title":"Metabolism of terallethrin in rats","volume":"6","author":"Mihara K","year":"1981","journal-title":"Nippon Noyaku Gakkaishi"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1996.tb06037.x"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2009.07.002"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9120(01)00217-X"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200216110-00004"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200216100-00004"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm900017f"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/0013-4694(72)90177-0"},{"key":"e_1_2_7_29_1","volume-title":"Clinical pharmacokinetics and pharmacodynamics","author":"Rowland M","year":"2009"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2005.01.013"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2008.03.051"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm0498351"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.105.005637"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1021\/tx00047a006"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3959(90)90073-M"},{"key":"e_1_2_7_36_1","first-page":"36","volume-title":"Antiepileptic Drugs","author":"White HS","year":"2002"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2005.06.008"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.628"}],"container-title":["Epilepsia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1528-1167.2010.02684.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1528-1167.2010.02684.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T21:26:13Z","timestamp":1698787573000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1528-1167.2010.02684.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,5]]},"references-count":37,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["10.1111\/j.1528-1167.2010.02684.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1528-1167.2010.02684.x","archive":["Portico"],"relation":{},"ISSN":["0013-9580","1528-1167"],"issn-type":[{"value":"0013-9580","type":"print"},{"value":"1528-1167","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8,5]]}}}